A1 Refereed original research article in a scientific journal

Treatment and outcomes of chronic coronary syndromes: the EORP EURECA imaging registry

Authors: Liga, Riccardo; Gimelli, Alessia; Podlesnikar, Tomaz; Cvijic, Marta; Pontone, Gianluca; Miglioranza, Marcelo Haertel; Guaricci, Andrea Igoren; Seitun, Sara; Clemente, Alberto; Sumin, Alexey; Vitola, Joao; Saraste, Antti; Paunonen, Christian; Sia, Ching-Hui; Paleev, Filipp; Sade, Leyla Elif; Zamorano, Jose Luis; Maroz-Vadalazhskaya, Natallia; Sredojevic, Mirjana; Anagnostopoulos, Constantinos; Macedo, Filipe; Knuuti, Juhani; Edvardsen, Thor; Cosyns, Bernard; Petersen, Steffen E.; Magne, Julien; Laroche, Cecile; Popescu, Bogdan A.; Delgado, Victoria; Neglia, Danilo; EURECA Investigators

Publisher: Oxford University Press (OUP)

Publication year: 2025

Journal:: European Heart Journal

Article number: ehaf594

Volume: 46

Issue: 39

First page : 3922

Last page: 3927

ISSN: 0195-668X

eISSN: 1522-9645

DOI: https://doi.org/10.1093/eurheartj/ehaf594

Web address : https://doi.org/10.1093/eurheartj/ehaf594

Funding information in the publication: 
Since the start of EORP, the following companies have supported the programme: Abbott Vascular (2011–2021), Amgen (2009–2018), AstraZeneca France (2014–2021), Bayer (2009–2018), Boehringer Ingelheim (2009–2019), Boston Scientific Corporation (2009–2012), Bristol-Myers Squibb and Pfizer (2011–2019), Daiichi Sankyo Europe (2011–2020), The Daiichi Sankyo Europe and Eli Lilly and Company (2014–2017), Edwards (2016–2019), Gedeon Richter (2014–2016), Menarini Group (2009–2012), Merck Sharp and Dohme France (2011–2014), Novartis Pharma (2014–2020), ResMed (2014–2016), Sanofi (2009–2011), Servier (2009–2018), Vifor Pharma (2019–2022).